From Genome to Therapy Integrating New Technologies with Drug Development

by Bock, Gregory R.; Cohen, Dalia; Goode, Jamie A.

• ISBN13: 9780471627449
• ISBN10: 0471627445
• Edition: 1st
• Format: Hardcover
• Copyright: 2000-11-08
• Publisher: WILEY

Summary

This important and exciting work brings together a high-calibre group of experts to discuss the practical application of genomic information to the development of drugs. Recent technological advances have led to a rapid acceleration in our ability to gather genetic data. The complete genetic sequences are now known for several organisms and accelerated programmes are in place for sequencing many other genomes, including human. The speed with which complete sequencing can be accomplished will continue to increase as new technologies come online. In principle, the scope for developing new diagnostic techniques and drugs is now greater than at any time in human history, but the pathway from genetic information to usable drug is a long and complex one. This major book covers such subjects as the current state of the art in squencing technology, the applications of these new technologies to sequencing the genomes of various organisms, and the challenge of proteomics. Additional contributions deal with legal and ethical implications of the new uses of genetic data, and functional genomics from the point of view of the pharmaceutical industry.

Author Biography

The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.

Table of Contents

Symposium on From genome to therapy: integrating new technologies with drug development, held at the Hotel Europe, Basel, Switzerland, 22-24 June 1999
Gregory R. Bock
Dalia Cohen
Jamie A. Goode
Introduction	1	(4)
J. C. Venter
Discussion	4	(1)
Electrophoresis-based fluorescent dideoxy-terminator sequencing	5	(9)
J.W. Efcavitch
Discussion	11	(3)
Genomic impact on pharmaceutical development	14	(5)
J. C. Venter
Discussion	15	(4)
From transcription regulation to cell cycle checkpoint	19	(8)
R. Cai
D. Fischer
Y. Yan-Neale
H. Xu
D. Cohen
Discussion	24	(3)
Mass spectrometry resurrects protein-based approaches in functional genomics	27	(6)
M. Mann
Discussion	29	(4)
A clinical molecular scanner to study human proteome complexity	33	(8)
D. Hochstrasser
J.-C. Sanchez
P.-A. Binz
W. Bienvenut
R. D. Appel
Discussion	38	(3)
From proteomics to functional analysis	41	(13)
J. van Oostrum
D Mueller
P. Schindler
Discussion	46	(8)
Microbial genome sequencing: new insights into physiology and evolution	54	(9)
C. M. Fraser
Discussion	58	(5)
Pharmacogenetics and pharmacogenomics in the discovery and development of medicines	63	(8)
A. D. Roses
Discussion	66	(5)
Mutagenesis and genomics in the mouse: towards systematic studies of mammalian gene function	71	(8)
S. D. M. Brown
Discussion	74	(5)
Biological annotation of the Drosophila genome sequence	79	(5)
G. M. Rubin
Discussion	82	(2)
Applications of high-density oligonucleotide arrays	84	(10)
R. J. Lipshutz
Discussion	90	(4)
Plasmodium falciparum: from genomic sequence to vaccines and drugs	94	(11)
S. L. Hoffman
D. J. Carucci
Discussion	100	(5)
Functional analysis of the yeast genome by precise deletion and parallel phenotypic characterization	105	(7)
E. A. Winzeler
H. Liang
D. D. Shoemaker
R. W. Davis
Discussion	109	(3)
Patenting genes and gene therapy: legal and ethical aspects	112	(10)
J. Straus
Discussion	117	(5)
Ethical issues: from genome to therapy	122	(9)
D. Magnus
Discussion	125	(6)
The impact of genomics on drug discovery	131	(5)
P. N. Goodfellow
Discussion	132	(4)
From genome to therapy: industry perspective	136	(23)
P. L. Herrling
Discussion	142	(8)
Final general discussion	150	(9)
Index of contributors	159	(2)
Subject index	161